On Friday 3 October, the European Commission announced that, at the request of 14 participating countries, it had signed a joint procurement framework contract with the Spanish pharmaceutical company HIPRA.
This agreement will enable participating countries to order up to 4 million doses of protein-based Covid-19 vaccine Bimervax®, adapted to the LP.8.1 variant. Orders will be placed according to national needs, with no minimum purchase required.
The contract, valid for up to two years, guarantees timely deliveries for the current vaccination campaign. The vaccine has received marketing authorisation from the Commission, after proving a strong immune response against LP.8.1 as well as cross-protection against new sublineages such as NB.1.8.1 and XFG.
Unlike the mRNA vaccines already available, Bimervax® is a protein-based vaccine. It contains specific fragments of the virus that trigger the body’s natural defences. It is packaged in single-dose vials, can be stored at between 2 and 8°C and has a shelf life of 12 months.
An added benefit is that HIPRA’s R&D, production and packaging activities are all located in Europe, which strengthens the Union’s strategic autonomy and reduces dependence on third countries.
To date, 38 countries have signed the EU’s Joint Procurement Agreement, a voluntary and flexible mechanism for jointly procurement of medical countermeasures and strengthening European preparedness for cross-border health crises. (Original version in French by Lionel Changeur)